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In a recent, population-based survey of 3,996 persons
in Indonesia, fluoroquinolone (FQ)-resistant Escherichia coli
was prevalent in the fecal flora of 6% of patients at hospital
admission and 23% of patients at discharge, but not among
healthy relatives or patients visiting primary healthcare cen-
ters (2%). Molecular typing showed extensive genetic diver-
sity with only limited clonality among isolates. This finding
suggests that independent selection of resistant mutants
occurs frequently. FQ-resistant isolates exhibited a higher
rate of spontaneous mutation, but sparser virulence profiles,
than FQ-susceptible isolates from the same population. The
resistant isolates belonged predominantly to phylogenetic
groups A(57%) and B1 (22%) but also to the moderately vir-
ulent group D (20%). Hypervirulent strains from the B2 clus-
ter were underrepresented (1%). Because FQ-resistant E.
coli can cause disease, especially nosocomial infections in
immunocompromised patients, spread of such strains must
be stopped.
E
scherichia coli is a common constituent of the gas-
trointestinal flora of most vertebrates, including
humans, and may be isolated from a variety of environ-
mental sources. While most strains are nonpathogenic, cer-
tain ones can cause a variety of intestinal and
extraintestinal infections. Pathogenicity is largely deter-
mined by gene-encoding virulence factors (VFs), such as
adhesins, toxins, and polysaccharide surface coatings (1).
Phylogenetic analysis showed that most E. coli strains fall
into 4 main phylogenetic groups, designated A, B1, B2,
and D (2). E. coli strains that cause extraintestinal infec-
tions derive predominantly from group B2 and, to a lesser
extent, group D. Strains of groups Aand B1 represent most
commensal strains and are largely devoid of virulence
determinants (3). Although strains harboring a robust
extraintestinal VF repertoire cluster predominantly in
groups B2 and D, isolates within each phylogenetic group
can be further classified as extraintestinal pathogenic E.
coli (ExPEC) or non-ExPEC depending on whether specif-
ic virulence traits are present (4,5).
The fluoroquinolones (FQs) are potent antimicrobial
agents used for the treatment and prophylaxis of infections
caused by gram-negative bacteria, including E. coli. FQ-
resistant E. coli has been reported increasingly during the
last decade in both the hospital environment and the com-
munity, which may ultimately limit the utility of these
broad-spectrum agents (6–8). Moreover, FQ-resistant E.
coli strains often show resistance to other drugs, such as
ampicillin, tetracycline, chloramphenicol, trimethoprim-
sulfamethoxazole, and gentamicin (7,9). Recent reports
have suggested that clinical FQ-resistant E. coli actually
tends to be less virulent than susceptible isolates. FQ-
resistant E. coli from hospitalized Dutch patients derived
predominantly from the low-virulence phylogenetic
groups A and B1. None of the 13 invasive isolates derived
from phylogenetic group B2 (10). In addition, evidence
suggests that clinical FQ-resistant E. coli isolates from
humans in Iowa were associated with a shift toward non-
B2 phylogenetic groups and to a lower overall virulence
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Verbrugh, Inge Gyssens, and Monique Keuters. genotype (4). FQ resistance may also be associated with
strains that intrinsically have a higher overall mutation
rate, since the resistance to FQs in E. coli involves the
accumulation of multiple spontaneously occurring point
mutations in several genes (9,11). These associations,
however, may depend on the strains’geographic or clinical
origin. 
In our study, we investigated these putative associations
in a well-defined collection of isolates from Indonesia. A
population-based survey of ≈4,000 people in 2 cities on the
island of Java (Surabaya and Semarang) was initiated in
2000 by the Antimicrobial Resistance in Indonesia,
Prevalence and Prevention study group to investigate the
level of carriage of resistant microorganisms. FQ-resistant
E. coli was prevalent in the fecal flora of 6% of patients at
hospital admission and 23% of patients at discharge but
not among healthy relatives or patients visiting primary
healthcare centers (2% in both groups) (ES Lestari, unpub.
data). In our study, we analyzed these FQ-resistant E. coli
isolates to elucidate their molecular epidemiology and vir-
ulence. To define clonal relatedness, we performed enter-
obacterial repetitive intergenic consensus (ERIC)
polymerase chain reactions (PCR). The phylogenetic back-
ground and virulence profile of these isolates were deter-
mined by PCR methods and compared with similar data
for FQ-susceptible E. coli isolated from the same popula-
tion. Finally, we examined the link between FQ resistance
and the intrinsic mutation rate.
Materials and Methods
Strains
The study group program surveillance was initiated to
determine the prevalence of antimicrobial resistance in
Indonesia. Four different groups of persons in Surabaya
and Semarang were studied for carriage of resistant
microorganisms in their stools. The 4 groups were patients
on the day of admission to the hospital (group 1), patients
on the day of discharge after >5 days of hospitalization
(group 2), patients visiting a primary healthcare center
(group 3), and healthy relatives or household members of
group 1 patients (group 4). In groups 1 and 2, rectal swabs
were taken from patients in the internal medicine, surgery,
gynecology/obstetrics, or pediatrics departments. The
specimens were collected from July to October 2001 in
Surabaya and from January to May 2002 in Semarang.
Further details on the methods of culturing will be pub-
lished elsewhere. A total of 5,535 E. coli isolates from
3,284 patients were cultured. Antimicrobial susceptibility
testing was performed for 1 isolate per patient. The overall
by-isolate prevalence of resistance to ciprofloxacin as
determined by disk diffusion was 8%. The prevalence of
resistance was highest among patients on the day of dis-
charge (18% in Surabaya and 27% in Semarang) and low-
est among patients visiting primary healthcare centers and
among family members of patients admitted to the hospi-
tal (2% in both groups). The prevalence of FQ-resistant E.
coli among patients who were tested on the day of admis-
sion was 8% in Surabaya and 4% in Semarang. We studied
196 FQ-resistant isolates in more detail. Seventy-five
(38%) of these were from Surabaya (19, 48, 4, and 4 iso-
lates from stated population groups 1, 2, 3, and 4, respec-
tively) and 121 (62%) from Semarang (13, 92, 11, and 5,
respectively). The FQ-resistant isolates were recovered
from patients from all 4 hospital departments in both cities.
In Semarang, 43% of these isolates were from surgery
departments and 41% were from internal medicine depart-
ments. In Surabaya, 43% of the isolates were from the
internal medicine department. All 196 ciprofloxacin-resist-
ant E. coli and 200 ciprofloxacin-susceptible E. coli (20
randomly chosen isolates from groups 1, 2, and 3 and 40
from group 4, from each city) were confirmed by Vitek 2
(bioMérieux, Marcy-l‘Etoile, France) according to the
manufacturer’s instructions and included in the molecular
analyses.
DNA Isolation
Bacterial DNA was isolated by using the MagNA Pure
LC with the MagNA Pure LC DNA Isolation Kit III for
bacteria and fungi (standard protocol; Roche Molecular
Biochemicals, Mannheim, Germany). DNA concentration
was assessed spectophotometrically. Samples were frozen
at –20°C until used.
Bacterial Typing by ERIC-PCR
ERIC-PCR was conducted with primers ERIC-1R and
ERIC-2 as described previously (8,12,13). The amplifica-
tion products were subjected to electrophoresis in a 1%
agarose gel and were stained with ethidium bromide (50
µg/mL). The ERIC-PCRs were performed by 1 technician
within 1 month. Profiles were visually analyzed by 2
microbiologists. Single-band differences in profiles among
strains led to the definition of separate genotypes.
Ambiguous isolates were retested and analyzed by 2 other
microbiologists.
Phylogenetic Analysis and Virulence Typing
Isolates were assigned to 1 of 4 main E. coli phyloge-
netic groups (A, B1, B2, and D) according to an estab-
lished triplex PCR assay, in which the 4 phylogenetic
groups yield distinct combinations of 3 possible PCR
products, chuA (heme transport), yjaA (unknown function
gene from E. coli K-12 genome), and TSPE4.C2 (anony-
mous fragment identified by subtractive hybridization)
(2,14). All isolates were screened for 5 ExPEC-defining
virulence markers, papA/papC,  sfa/focDE,  afa/draBC,
RESEARCH
1364 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 9, September 2005kpsM II, and iutA. Based on previous statistical analyses of
similar data, from collections within which each isolate’s
ExPEC status could be inferred based on ecologic source
or experimental virulence, isolates were classified as
ExPEC if positive for >2 of these 5 defining virulence
markers (4). All isolates were also screened for hlyD
(hemolysin), another ExPEC-associated VF. Subsequently,
all isolates that satisfied molecular criteria for ExPEC were
screened for 32 additional virulence markers1. These viru-
lence genes were detected by a combination of multiplex
PCR and dot-blot hybridization with primers specific for
internal or flanking sequences and probes generated and
labeled with these primers; this method was previously
validated by using dot-blot hybridization with defined con-
trol strains (15). AVF score was calculated for each strain
as the sum of all VF genes for which the strain tested pos-
itive. In all of these PCR assays, the identity of the PCR
products was deduced by comparing their size to molecu-
lar size standards in ethidium bromide–stained agarose
gels. Appropriate positive and negative controls were
included in each run.
Mutation Rate Analysis
The mutation rate was determined for 20 randomly
selected isolates from phylogenetic group A (10 FQ-sus-
ceptible and 10 FQ-resistant) by monitoring the isolates’
capacity to generate mutations conferring resistance to
rifampin, as described previously (9,16). Forty independ-
ent cultures of each of the 20 strains were set up in Luria
broth. After overnight incubation, equal concentrations of
cultures were suspended in 0.85% NaCl. The suspensions
were spread on Luria agar plates containing 100 µg/mL
rifampin and incubated overnight. For each strain, the pro-
portion of cultures giving no resistant mutants was used to
calculate the mutation rate per cell per generation accord-
ing to the fluctuation test of Luria and Delbrück. To avoid
confounding by variation in phylogenetic background,
only phylogenetic group A isolates were investigated. For
comparisons of results, we used the relative mutation rate,
which was defined as the rate relative to the rate for E. coli
strain Nu14 (5 × 10–9 per cell per generation) (9).
Statistical Analysis
All data were analyzed by using the statistic software
packages SPSS version 10.0 (SPSS, Chicago, IL, USA)
and EpiInfo version 5.00 (Centers for Disease Control and
Prevention, Atlanta, GA, USA). Chi-square or Fisher exact
tests (2-tailed) were used when appropriate for compar-
isons of proportions. Comparisons involving VF scores
and relative mutation rates were analyzed by using the
Mann-Whitney U test. The criterion for statistical signifi-
cance was a p value <0.05. 
Results
Spread of FQ-resistant E. coli 
Genetic heterogeneity among the 196 FQ-resistant E.
coli was assessed by ERIC-PCR. We documented 158 dif-
ferent patterns, designated types 1–158, which indicated a
genetically diverse collection of strains. Twenty pairs of
isolates with identical profiles were identified, and 9 dis-
tinct multiple-isolate clones were represented by isolates
from 3 patients each. The limited number of shared geno-
types was mainly recovered from group 2 patients, i.e.,
patients at the time of discharge from the hospital, 49 (73%)
of 67 isolates. Among the total number of 140 isolates from
group 2, we identified 119 different ERIC-PCR profiles. 
Type 37 occurred in 3 patients from the internal medi-
cine department in Surabaya; all 3 patients were present
within this department on the same day. The finding of this
unique isolated cluster can be explained by patient-to-
patient transmission or a nonpatient-associated environ-
mental source. This explanation was not further examined
in this study. Type 90 was isolated from 2 patients on the
day they were discharged from the internal medicine
department in Semarang. Samples were collected on con-
secutive days. An isolate with an identical ERIC-PCR pat-
tern was found in the same period in the same hospital in a
pediatric patient at discharge. No further obvious cluster-
ing in time and place was observed among isolates from
the 9 multiple-strain clusters.
Phylogenetic Analysis
PCR-based phylotyping showed that the 200 FQ-sus-
ceptible isolates were predominantly from phylogenetic
groups A (52%) and B1 (30%) (Table 1). The 196 FQ-
resistant isolates also mainly derived from phylogenetic
groups A (57%) and B1 (22%), but some derived from the
moderately virulent phylogenetic group D (20%).
Hypervirulent strains from the B2 cluster were underrepre-
sented (1%). Eighteen (67%) of the 27 isolates from the 9
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1ExPEC: papEF (P fimbrial tip pilins); papG (P adhesin); papG
alleles I, II, and III; sfaS (S fimbriae); focG (F1C fimbriae); iha
(putative adhesin-siderophore); bmaE (M fimbriae); gafD (G fimbri-
ae); F17a (F17a fimbriae); clpG (CS31A adhesin); afaE8 (afimbri-
al adhesin VIII); fimH (type 1 fimbriae); cnf1 (cytotoxic necrotizing
factor); cdtB (cytolethal distending toxin); ireA (siderophore recep-
tor); sat (secreted autotransporter toxin); astA (S-like enterotoxin);
iroN (siderophore receptor); fyuA (yersiniabactin receptor); kpsM
II, K1, and K2 (kpsM II variants; group 2 capsule); kpsM III (group
3 capsule); rfc (O4 lipopolysaccharide synthesis); cvaC (colicin V);
traT (serum-resistance associated outer membrane protein); ibeA
(invasion of brain endothelium); ompT (outer membrane protease
T);  iss (increased serum survival); usp (uropathogenic specific
protein);  malX (marker for pathogenicity-associated island from
strain CFT073); and H7 fliC variant (flagellin).distinct clones that were represented by 3 isolates each
belonged to group A. 
Table 1 shows that the resistant isolates were signifi-
cantly depleted for phylogenetic group B2 and enriched for
group D, when compared with the susceptible isolates.
These shifts in phylogenetic distribution were significant
both overall and specifically in Semarang, whereas a sim-
ilar but nonsignificant trend was observed in Surabaya. 
The phylogenetic distribution of all 396 isolates among
the 2 cities was highly similar (data not shown).
Comparisons of the distributions among the 4 population
groups showed that group D isolates were more often
obtained from patients sampled on the day of discharge
than from other population groups (37 [21%] of the 180
group 2 isolates belonged to group D versus 25 [12%] of
the 216 nongroup 2 isolates, p = 0.01). Stratification
showed, however, that this association was due to the
excess prevalence of FQ-resistant group D isolates among
the group 2 patients. Furthermore, B2 isolates were signif-
icantly more prevalent in group 3, patients visiting public
healthcare centers (7 [13%] of the 55 group 3 isolates
belonged to group B2 versus 10 [3%] of the 341 nongroup
3 isolates, p = 0.004).
Virulence Typing
All E. coli isolates were tested for a set of virulence fac-
tors to allow an inference as to their pathogenic potential.
The overall prevalence of the 5 defining ExPEC VFs
ranged from 2% (sfa/focDE) to 33% (iutA) (Table 1). The
FQ-resistant isolates were significantly depleted for papA,
papC, sfa/focDE, afa/draBC, hlyD, and kpsM II (Table 1),
when compared with the susceptible isolates. Accordingly,
40 (20%) FQ-susceptible E. coli isolates, but only 4 (2%)
FQ-resistant isolates (2%), were classified as ExPEC, as
they exhibited >2 of the 5 key ExPEC VFs (p<0.001).
Thus, FQ resistance was associated with reduced inferred
virulence. All FQ-resistant E. coli isolates from the 9 dis-
tinct clones that were represented by 3 patients each were
found to be non-ExPEC. 
The distribution of the 6 screening VFs was also ana-
lyzed in relation to the 4 phylogenetic groups (Table 2).
Each VF was broadly distributed, occurring in >3 phyloge-
netic groups. However, papA, papC, kpsM II, hlyD, and
sfa/focDE were all significantly associated with phyloge-
netic group B2. Accordingly, 53% of the phylogenetic
group B2 isolates qualified as ExPEC versus 9% of the
non-B2 isolates (p<0.001) (Tables 2 and 3).
The 44 ExPEC isolates were studied in more detail
(Table 3). The ExPEC isolates derived mainly from phylo-
genetic groups A (36%) and B1 (32%), with the 4 FQ-
resistant ExPEC isolates belonging to groups A(n = 2) and
D (n = 2). Many (36%) ExPEC isolates originated from
patients on the day of discharge. Both of the FQ-resistant
ExPEC isolates from group 2 were from patients in the sur-
gical ward in Semarang. Again, no evidence for clonality
was seen. The 4 resistant ExPEC isolates exhibited sparse
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isolates. These isolates lacked classic ExPEC VFs such as
focG, hlyD, and cnf1. Four other VFs, iha, sat, fyuA, and
malX, were more prevalent among susceptible, rather than
resistant, ExPEC isolates. Only ibeA was more prevalent
among the resistant isolates. The VF iutA was detected in
all FQ-resistant ExPEC isolates and in 27 (68%) of the 40
FQ-sensitive isolates. This difference was not significant.
Aggregate VF scores were lower among FQ-resistant
ExPEC isolates (median 6, range 4–8) than among the 40
FQ-susceptible ExPEC isolates (median 10, range 3–16, p
= 0.024). 
Mutation Rate
The link between mutation rate and resistance to FQs
was studied, as the rate of mutation accumulation might be
a factor in the development of FQ resistance. The 10 FQ-
susceptible isolates had relative mutation rates of <0.52
(median rate 0.32, range 0.03–0.52), whereas the 10 FQ-
resistant E. coli exhibited relative mutation rates of >0.55
(median rate 0.97, range 0.55–4.58) (p<0.001) (Figure).
Discussion
In this study, we investigated the epidemiology and vir-
ulence characteristics of FQ-resistant E. coli collected dur-
ing a large, population-based survey of ≈4,000 people in 2
cities in Indonesia (Surabaya and Semarang). The overall
prevalence of resistance to ciprofloxacin was 8%, but in
the fecal flora of patients at time of discharge from the hos-
pital the prevalence was 23%. 
Dissemination of FQ-resistant E. coli and Mutation Rate
Three possible explanations for the high prevalence of
FQ-resistant E. coli among patients that had been hospital-
ized for >5 days must be considered: transferable resist-
ance, clonal spread, and mutation-based selection of resist-
ance fostered by the use of antimicrobial agents.
Transferable plasmid-mediated quinolone resistance has
been described recently in E. coli from China (17). Wang
et al. found that 6 (8%) of 78 ciprofloxacin-resistant E. coli
strains from a hospital in Shanghai contained qnr.
However, from the present study we cannot draw any con-
clusion about the contribution of this mechanism in
Indonesia. As for clonal spread, molecular typing showed
extensive genetic diversity among FQ-resistant isolates in
Indonesia. We identified a few distinct multiple-isolate
clones in the hospital environment. Although all these
clonal strains were shown to be non-ExPEC, they may still
pose a health threat, especially to immunocompromised
Fluoroquinolone-resistant Escherichia coli
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Figure. Box plot of relative mutation rate of 10 fluoroquinolone
(FQ)-resistant (FQREC) and 10 FQ-sensitive (FQSEC)
Escherichia coli.patients in hospital settings. Nosocomial outbreaks of
infections caused by disseminating FQ-resistant clones
have already been described (8). However, in our study,
limited clonality among isolates was found, which sug-
gests that other factors contribute more to the high preva-
lence of FQ-resistant E. coli among hospitalized patients.
To determine whether mutation-based resistance fos-
tered by selection pressure contributed to the prevalence of
FQ-resistant E. coli in Indonesia, we performed a mutation
rate analysis of selected isolates. We found a strong corre-
lation between resistance and an elevated mutation rate.
This finding agrees with a recent report from Komp
Lindgren et al., in which high mutation rates of E. coli
strains from urinary tract infections were strongly associat-
ed with FQ resistance (9). To demonstrate that this muta-
tion-based resistance was selected for by the use of FQs, we
must know the consumption figures of the quinolones. In
other reports, evidence suggests that the use (and misuse) of
ciprofloxacin in human and animal medicine may predis-
pose to an increase in infections with resistant E. coli (8).
As information on the use of FQs in Indonesia is currently
not available, we cannot draw any conclusions on a poten-
tial link between antimicrobial drug use, selection pressure,
and mutation-based resistance. Thus, based on the large
clonal diversity of the FQ-resistant E. coli and the resistant
isolates that have a slightly elevated mutation rate relative
to FQ-sensitive isolates, independent emergence of new
resistant mutants likely occurs regularly in this setting.
Phylogenetic Typing and Virulence Profiling
Phylogenetic typing and virulence profiling were per-
formed to investigate whether a potential clinical hazard
was associated with the presence of these isolates. Our
data on the distribution of phylogenetic groups among the
396 E. coli isolates are consistent with those of most other
studies. In an examination of human commensal E. coli
strains, the frequencies of B2 strains were found to be 1
(2%) of 55 in Mali, 6 (11%) of 56 in France, and 11 (19%)
of 57 in Croatia (18). In our study, 4% of the isolates over-
all were of B2 origin. However, the results from a report
by Zhang et al. do not agree with our data (19). B2 strains
accounted for 42 (48%) of 88 commensal rectal strains
from healthy college-aged women in Michigan. Likewise,
Sannes et al. noted a high prevalence of group B2 among
rectal isolates from hospitalized, elderly, male veterans in
Minnesota (20). Differences may be due to geographic
variation, differences in host population characteristics, or
differences in strain characteristics such as antimicrobial
resistance.
We did not observe a significant shift toward low-viru-
lence phylogenetic groups for resistant isolates, as was
reported by Johnson et al. (10). However, we confirmed
that the isolates were notably depleted for phylogenetic
group B2 and enriched for group D. We also confirmed
that FQ-resistant E. coli exhibited sparser virulence pro-
files. The most prevalent VF was iutA, which was detected
in 36% of the resistant isolates; however, this VF is less
common in virulent group B2 strains (1). Accordingly,
only 2% of the resistant isolates were found to be ExPEC.
These 4 isolates also lacked the VFs iha, sat, fyuA, and
malX as compared to the FQ-susceptible ExPEC. Whether
ExPEC strains cause infection in humans depends on sev-
eral other factors, including susceptibility of the host.
Therefore, that many (36%) of the 44 ExPEC isolates were
from group 2 patients who had been hospitalized for >5
days is of concern. When patients become colonized with
FQ-resistant ExPEC strains in the hospital, they presum-
ably will have an increased risk of acquiring a nosocomial
infection and, when discharged with such a strain, also for
community-acquired infection; in such case, an optimal
therapy will be more difficult to select. Of note, a relation-
ship has recently been shown to exist between
ciprofloxacin-resistance in E. coli and the production of
extended-spectrum  β-lactamases, which would further
limit therapeutic options (21).
Our observations provide insight into the epidemiology
and virulence characteristics of FQ-resistant E. coli from
stools of patients and healthy participants in Indonesia.
The high prevalence of FQ-resistant E. coli in the hospital
environment seems to be primarily due to a combination of
limited clonal spread and the spontaneous emergence of
resistant strains, possibly fostered by selection pressure.
Transferable resistance, however, cannot be ruled out as an
additional explanation in the present study and will be the
subject of future investigations. Although the resistant iso-
lates mainly belong to phylogenetic groups A and B1 and
show a low virulence profile, similar strains have caused
disease in humans (3,10). The data support the need to
implement strict infection control measures in hospitals
and to promote and monitor the prudent use of antimicro-
bial drugs. Continued surveillance of the changes of resist-
ance patterns and virulence profiles of clinical and
nonclinical E. coli isolates is warranted. 
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